Burning Rock Biotech Limited

NasdaqGM:BNR Stock Report

Market Cap: US$67.5m

Burning Rock Biotech Past Earnings Performance

Past criteria checks 0/6

Burning Rock Biotech's earnings have been declining at an average annual rate of -11%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 8.4% per year.

Key information

-11.0%

Earnings growth rate

15.8%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate8.4%
Return on equity-66.0%
Net Margin-83.7%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Jun 21
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Mar 25
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Feb 01
There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12
Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23
We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

Burning Rock Localizes As Investors Grow Impatient

Jun 06

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Nov 17

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Aug 27
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Jul 23
A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

May 13
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

Burning Rock Biotech Expands Test Portfolio In Bid For Growth

Dec 30

Burning Rock inks license pact with Oncocyte Corporation

Dec 15

Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS

Dec 04

Burning Rock Biotech EPS misses by $0.08, beats on revenue

Nov 20

Revenue & Expenses Breakdown

How Burning Rock Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGM:BNR Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24511-428540253
30 Jun 24510-567640288
31 Mar 24521-590638319
31 Dec 23537-654686347
30 Sep 23559-708732375
30 Jun 23586-764788397
31 Mar 23570-895900397
31 Dec 22563-971939422
30 Sep 22568-1,006965434
30 Jun 22540-945925394
31 Mar 22537-887853410
31 Dec 21508-797793368
30 Sep 21492-702720339
30 Jun 21490-659674338
31 Mar 21469-564570301
31 Dec 20430-472462264
30 Sep 20387-450390233
30 Jun 20367-389316202
31 Mar 20345-347291166
31 Dec 19382-334285157
30 Sep 19358-268248137
31 Dec 18209-232191105
31 Dec 17111-18514449

Quality Earnings: BNR is currently unprofitable.

Growing Profit Margin: BNR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BNR is unprofitable, and losses have increased over the past 5 years at a rate of 11% per year.

Accelerating Growth: Unable to compare BNR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: BNR has a negative Return on Equity (-65.96%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 01:08
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Burning Rock Biotech Limited is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Bo LiBofA Global Research
null nullChina International Capital Corporation Limited
Ziyu HeChina International Capital Corporation Limited